V8 Peptides — Engineered Performance
Research Library
What Is IGF-1 LR3? A Plain-Language Research Guide
IGF-1 LR3Overview

What Is IGF-1 LR3? A Plain-Language Research Guide

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is IGF-1 LR3? IGF-1 LR3 (Long R3 IGF-1) is a laboratory analog of human insulin-like growth factor 1. It is 83 amino acids long, against 70 for the native protein, because of two changes: arginine replaces glutamic acid at position 3, and a 13-residue extension sits at the N-terminus. Those changes sharply reduce binding to IGF-binding proteins (IGFBPs), the carrier proteins that normally hold most IGF-1 in an inactive reserve. In cell culture this makes the analog a stronger, more predictable input than native IGF-1 where binding proteins are present. It is supplied for laboratory research use only; not for human consumption.

Searches for "what is IGF-1 LR3" usually come from someone who has met the name in a reagent catalog or a paper and wants a clear definition before going further. This guide starts from the beginning: what the IGF system is, what is different about LR3, which published experiments established the difference, and what the molecule is used for on the bench. Deeper structural detail is covered in the IGF-1 LR3 explained article and the full IGF-1 LR3 research overview; this page is the plain-language entry point.

Step one: what IGF-1 is

Insulin-like growth factor 1 is a 70-amino-acid protein hormone that signals through the type 1 IGF receptor (IGF1R), a receptor tyrosine kinase. It sits in the middle of a regulatory cascade that textbooks call the growth hormone–IGF axis. Miller and colleagues' history of the IGF system describes the components as the peptide hormones IGF-I and IGF-II, their cell-surface receptors, and the IGF-binding proteins and IGFBP proteases that regulate how much hormone reaches a receptor in a given tissue, and it traces the idea from the early somatomedin hypothesis to modern knockout and cell-level work.

The reason this matters for LR3 is that IGF-1 rarely travels alone. Bach's review of the IGF-binding proteins explains that IGFBPs 1–6 bind IGFs, but not insulin, with high affinity. They were first identified as serum carriers and passive inhibitors of IGF action; later work showed that they can also potentiate IGF action in some circumstances, and that they have IGF-independent roles in proliferation, survival, migration, senescence, autophagy and angiogenesis. In any biological fluid or serum-containing medium, the effective amount of free, receptor-available IGF-1 is therefore a function of both the amount added and the binding proteins present.

Step two: how the receptor responds

At the receptor end, cryo-EM work by Li and colleagues described the full-length IGF1R–IGF1 complex in its active state. Their abstract reports that only one IGF1 molecule binds the asymmetric, Γ-shaped receptor dimer, that the binding site is formed by the L1 and CR domains of one protomer and the α-CT and FnIII-1 domains of the other, and that this arrangement explains the negative cooperativity seen in IGF1 binding. For a reader meeting the topic for the first time, the useful takeaway is simple: one receptor dimer, one ligand, a defined signaling start point. Downstream readouts commonly used in the lab are the PI3K/Akt and MAPK pathways, which the IGF-1 LR3 product page lists among its research applications.

Step three: what changes in LR3

The IGF-1 LR3 sequence differs from native IGF-1 in two ways, both described on the product page. The "R3" is arginine in place of the glutamic acid at position 3. The "Long" is a 13-amino-acid extension added at the N-terminus. The result is an 83-residue protein of roughly 9.1 kDa. The product page gives the molecular formula as C400H625N111O115S9, a 1 mg vial size, a purity of ≥98% by HPLC and a lyophilized powder form, and notes that the sequence and identity are reported on the certificate of analysis where one is published.

In practical terms the two changes act together to weaken the grip of IGFBPs on the molecule. Native IGF-1 is buffered by binding proteins; LR3 largely escapes that buffering. The receptor still recognizes it, so the ligand reaches IGF1R more freely in systems that contain binding proteins.

FeatureNative IGF-1IGF-1 LR3
Length70 amino acids83 amino acids
Position 3Glutamic acidArginine
N-terminusNative13-residue extension
Approximate massAbout 7.6 kDaAbout 9.1 kDa
Binding to IGFBPsHigh affinitySharply reduced
ReceptorIGF1RIGF1R

The experiment that defined the difference

The comparison most often cited for LR3 comes from Ballard and colleagues. Their 1993 study compared IGF-I and LR3IGF-I in a series of experiments. According to the abstract, IGF-I had approximately 1000-fold higher affinity than LR3IGF-I toward IGFBP-3, IGFBP-4, total rat plasma IGFBPs and L6 myoblast binding proteins. In cultured L6 myoblasts, the reduced association with IGFBPs gave LR3IGF-I a 5–10-fold greater biological potency. In rats given the peptides chronically for 14 days, LR3IGF-I was six-fold more potent than IGF-I on growth measurements, in line with the in vitro difference.

The same paper contains a result that surprises people who assume "modified" means "longer-lived in the body." LR3IGF-I was removed from plasma much more rapidly than IGF-I, a difference the authors attributed to its poor association with plasma binding proteins. They confirmed the logic in pregnant rats, where IGFBP levels are markedly reduced: in that condition only the clearance of IGF-I changed, becoming almost as rapid as that of LR3IGF-I. The lesson is that LR3 is not a stabilized IGF-1 in the sense that semaglutide is a stabilized GLP-1. It is a binding-protein-evading IGF-1. Its advantage is reduced sequestration, which matters in culture media where there is no clearance organ at all.

Why this suits cell culture

In a dish there are no kidneys or liver to clear a growth factor, but there may be binding proteins, either secreted by the cells or carried in with serum. A reagent that ignores those proteins gives a more predictable effective concentration. That is why the product page lists serum-free media supplementation, IGF-1 receptor signaling assays and binding-protein interaction studies as typical uses. A researcher who wants to probe IGF1R signaling without the confounder of IGFBP secretion can use LR3 in parallel with native IGF-1; any difference between the two arms then points to binding-protein influence on the readout.

Experimental questionTypical designWhat the LR3 arm adds
Is IGFBP secretion shaping the response?Native IGF-1 versus LR3 at matched concentrationsA larger LR3 response suggests binding-protein buffering of the native ligand
Does pathway activation occur at the receptor?Phospho-Akt and phospho-ERK readouts over a time courseA persistent, binding-protein-independent input
Can serum be removed?Defined medium with LR3 as the growth-factor supplementA single defined ligand in place of undefined serum factors
How do binding proteins interact?Add recombinant IGFBPs to each armThe degree to which each analog is sequestered

Handling a small protein, not a small peptide

At around 9.1 kDa with internal disulfide bonds, IGF-1 LR3 behaves more like a protein than like a short peptide, and routine peptide habits do not all carry over. Adsorption to plastic is a recognized source of loss for peptides generally; Goebel-Stengel and colleagues published a paper on the importance of choosing the optimal plasticware and glassware in studies involving peptides, and the point applies with extra force to dilute stocks of a small protein. Practical consequences include low-binding tubes, minimal transfers and gentle mixing. The stock concentration is simply the vial mass divided by the diluent volume, and the reconstitution calculator handles the arithmetic. Full storage guidance on the product page reads: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light. A step-by-step approach to preparing a lyophilized vial is in how to reconstitute a lyophilized peptide, and the broader storage principles are in storing research peptides.

Checking what you have

Because identity is more complicated for an 83-residue protein than for a hexapeptide, a certificate of analysis deserves a careful read. Look for the compound name, the sequence or identity statement, the measured HPLC purity, the batch number and the test date; how to read a COA explains each field, and certificates are listed in the COA library where published. Chromatographic purity does not guarantee correct folding or bioactivity, so groups that need activity data often run a small bioassay before committing a long experiment. The reasoning behind pairing HPLC with identity testing is covered in HPLC versus mass spectrometry.

Context: why the IGF system draws wide interest

IGF signaling is studied across growth biology, metabolism and cancer biology; Pollak and colleagues' Nature Reviews Cancer article, for example, is titled "Insulin-like growth factors and neoplasia." That breadth is also a reason for care: a reagent that activates IGF1R strongly should be used only in systems designed for it, with appropriate controls. For related reading on the compound, see IGF-1 LR3 versus IGF-1 DES and the product-focused IGF-1 LR3 purity testing. Other catalog compounds are on the research shop page.

Frequently asked questions

What does LR3 stand for in IGF-1 LR3?

"R3" refers to arginine replacing the native glutamic acid at position 3, and "Long" refers to the 13-amino-acid extension at the N-terminus. Together they give an 83-residue analog.

How is IGF-1 LR3 different from IGF-1?

Native IGF-1 has 70 residues and binds IGF-binding proteins with high affinity. LR3 carries the Arg3 substitution and an N-terminal extension, which sharply reduce that binding while leaving the analog able to engage the IGF-1 receptor.

Why does reduced binding-protein affinity matter?

Binding proteins sequester IGF-1 and can also modulate its action. In a cell culture medium with secreted or serum-derived binding proteins, an analog that escapes them gives a more consistent free concentration at the receptor.

Is IGF-1 LR3 longer-lived than IGF-1 in the body?

Not by the older rat data. Ballard and colleagues reported that LR3IGF-I was cleared from plasma more rapidly than IGF-I, because it associates poorly with plasma binding proteins. Its distinct property is reduced binding-protein interaction, not slower clearance.

How much more potent is LR3 in culture?

In L6 myoblast cultures in that study, the reduced association with binding proteins gave LR3IGF-I a 5–10-fold greater biological potency than IGF-I. Results depend on the cell type and on how many binding proteins are present.

What size and form does the V8 vial come in?

The product page lists a 1 mg vial of lyophilized powder with stated purity of ≥98% by HPLC and the molecular formula C400H625N111O115S9, supplied in a sealed clear glass research vial.

Why does a 9 kDa protein need special handling?

Larger molecules tend to adsorb to surfaces and can be sensitive to agitation. Low-binding plastics, gentle swirling and single-use portions reduce loss and variability, and a carrier protein is sometimes added when the assay allows.

How is the stock concentration worked out?

Concentration equals vial mass divided by diluent volume. The calculator on this site performs that arithmetic and any serial dilutions; record the numbers with the experiment.

Does HPLC purity prove that the protein is active?

No. HPLC reports the proportion of the main peak, not folding or receptor activity. Identity confirmation and, where activity matters, a small bioassay are separate checks.

Which pathways are usually measured with LR3?

PI3K/Akt and MAPK readouts downstream of IGF1R are the ones named on the product page, often as phosphorylation time courses compared against native IGF-1.

All material discussed is supplied for laboratory research use only; not for human consumption.

Related reading: High-Purity IGF-1 LR3: Folding and Identity Checks.

References

  1. Miller BS, et al. The history of the insulin-like growth factor system. Horm Res Paediatr. 2022;95(6):619-630. doi:10.1159/000527123
  2. Bach LA. IGF-binding proteins. J Mol Endocrinol. 2018;61(1):T11-T28. doi:10.1530/JME-17-0254
  3. Li J, et al. Structural basis of the activation of type 1 insulin-like growth factor receptor. Nat Commun. 2019;10:4567. doi:10.1038/s41467-019-12564-0
  4. Ballard FJ, et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul. 1993;3(1):40-44. PMID: 7683526
  5. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505-518. doi:10.1038/nrc1387
  6. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.